Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Repeated- Dose, Parallel-Group Comparison of Safety, Efficacy, and Quality of Life Measures With Dilaudid CR (Hydromorphone HCI) or Oxycontin (Oxycodone HCI) in Patients With Chronic Osteoarthritis

NCT00399048 is registered in ClinicalTrials.gov with Alza Corporation, DE, USA as lead sponsor.

NCT NCT00399048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00399048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Repeated- Dose, Parallel-Group Comparison of Safety, Efficacy, and Quality of Life Measures With Dilaudid CR (Hydromorphone HCI) or Oxycontin (Oxycodone HCI) in Patients With Chronic Osteoarthritis
Lead sponsor
Alza Corporation, DE, USA
Phase
Phase 3
Overall status
Completed
Start date
Not reported
Completion date
May 31, 2001
Enrollment
140 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis, hip, osteoarthritis, knee